News Articles

International Consensus Statement on Postoperative Anemia Management Recommends Noninvasive Hemoglobin Measurement... NEUCHATEL, Switzerland -Wednesday 14 November 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today that a new consensus statement on postoperative anemia management was published in Anaesthesia by an international panel of clinicians specializing in patient blood management, which includes clear guidance on the use and benefits of...

New Study Evaluates the Ability of Masimo ORi™ to Help Clinicians Reduce Hyperoxemia in Mechanically Ventilated... -Tuesday 2 October 2018  

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the 2018 Congress of the French Society of Anesthesia and Resuscitation (SFAR) in Paris in which researchers at CHU Angers in France investigated the ability of Masimo ORi™ (Oxygen Reserve Index)...

New Study Compares Two Methods of Guiding Goal-Directed Fluid Therapy, Noninvasive MasimoPVi® and... -Thursday 6 September 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the findings of a study recently published in BMC Anesthesiology in which researchers at University Hospital Linköping, Sweden, compared the performance of goal-directed fluid therapy (GDFT) using invasive esophageal Doppler to GDFT...

New Study Evaluates the Ability of Masimo ORi™ to Reflect Oxygenation During Moderate Hyperoxia -Tuesday 28 August 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the findings of a study recently published in Anesthesia & Analgesia in which researchers at the University of Groningen, the Netherlands, and Ghent University, Belgium, investigated the ability of Masimo ORi™ (Oxygen Reserve Index) to...

New Study Investigates the Utility of Home Monitoring Using Masimo SET® Pulse Oximetry to Screen Children... -Tuesday 14 August 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers investigated whether home pulse oximetry monitoring might be a useful initial screening method of determining which children with Down syndrome (DS) – who are at high risk...

New Study Investigates the Utility of Masimo PVi® as Part of Goal-Directed Fluid Management in Patients Undergoing... -Monday 16 July 2018  

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Kocaeli University in Turkey compared the performance of conventional fluid management (CFM) to goal-directed fluid management (GDFM) using Masimo PVi® (pleth variability...

New Study Investigates the Utility of Masimo ORi™ (Oxygen Reserve Index) in Providing Early Detection of Blood... -Monday 2 July 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the findings of a study in which researchers evaluated the ability of Masimo ORi™ (Oxygen Reserve Index) to detect declining blood oxygenation prior to standard oxygen saturation (SpO2) monitoring in patients undergoing elective...

United Arab Emirates Ministry of Health & Prevention Adopts National CCHD Newborn Screening Program Using Masimo... -Thursday 28 June 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today that the United Arab Emirates (UAE) Ministry of Health & Prevention (MOHAP) is adopting a national screening protocol for critical congenital heart disease (CCHD) for all newborns. As part of the program launch, the MOHAP is equipping 9...

New Study Investigates the Utility of Masimo SedLine® Patient State Index in Monitoring Anesthesia... -Tuesday 12 June 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at Euroanaesthesia 2018 in which researchers compared Masimo Patient State Index (PSi), a processed EEG parameter provided by SedLine® brain function monitoring (in this study, first generation...

New Study Investigates the Utility of Continuous Noninvasive Hemoglobin Measurement With Masimo... -Tuesday 5 June 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ:MASI) announced today the findings of an abstract presented at Euroanaesthesia 2018 in which researchers compared Masimo noninvasive and continuous hemoglobin (SpHb®) to intermittent and invasive lab hemoglobin (LabHb) in reflecting iatrogenic hemodilution...

New Study Investigates the Economic Impact and Utility of Continuous Noninvasive Hemoglobin Measurement with Masimo... -Monday 14 May 2018

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers evaluated the utility of Masimo noninvasive and continuous hemoglobin (SpHb®) in reducing the number of unnecessary blood transfusions, thus reducing costs and improving...

New Study Investigates the Utility of Masimo SpHb® in Post-operative Red Blood Cell (RBC) Transfusion... -Friday 20 April 2018  

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the 2018 Annual Meeting of the Network for the Advancement of Patient Blood Management, Haemostatis and Thrombosis (NATA), in which researchers investigated the utility of Masimo noninvasive and...

New Study Investigates the Performance of Masimo SpHb® During Acute Bleeding and After Fluid... -Tuesday 13 March 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Cairo University in Egypt evaluated the accuracy and trending of Masimo noninvasive and continuous hemoglobin (SpHb®), referenced to an invasive laboratory hemoglobin...

Leading Nephrology Care Center in India Adopts Masimo Technologies Across Continuum of Care -Wednesday 28 February 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today that NU Hospitals, a leading nephrology care center in India, has standardized on Masimo technologies across the continuum of care. NU Hospitals have entered into a strategic partnership with Masimo to adopt technologies in their...

New Study Evaluates the Performance of Masimo PVi® as a Predictor of Fluid Responsiveness in Mechanically... -Monday 12 February 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Bülent Ecevit University in Zonguldak, Turkey compared two noninvasive methods of predicting fluid responsiveness in mechanically ventilated patients in the intensive...

Masimo Announces CE Marking of Eve™ CCHD Newborn Screening Application for the Rad-97™ Pulse... -Thursday 8 February 2018  

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse CO-Oximeter®. Eve combines the power of Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry...

New Study Investigates the Clinical Utility of ORi™, Masimo Oxygen Reserve Index™, in Obese Patients -Tuesday 23 January 2018

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the annual meeting of the Society for Technology in Anesthesia (STA) in Miami, Florida. In the study, researchers at the UC Davis School of Medicine evaluated the potential clinical utility of...

Masimo Announces CE Marking and Release of Oxygen Reserve Index™ rainbow Lite Sensors -Tuesday 2 January 2018  

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the CE marking and release of RD rainbow Lite SET™ sensors, which enable the monitoring of Masimo Oxygen Reserve Index™ (ORi™) and RPVi™, an improved PVi® that allows clinicians to assess fluid responsiveness noninvasively and...

Artemis Hospital Becomes First in India to Adopt Masimo Patient SafetyNet™ Across All Hospital Care Areas -Saturday 2 December 2017

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today that Artemis Hospital, one of the leading multi-specialty hospitals in the Delhi-NCR region of India, is adopting Masimo Patient SafetyNet™*, a supplemental remote monitoring and clinician notification system, across all hospital care...

Study Evaluates Performance of Masimo iSpO2® Rx Smart Device-Paired Pulse Oximeter in Screening Newborns... -Wednesday 6 September 2017

(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers in Maastricht, The Netherlands evaluated the performance of Masimo iSpO2® Rx in screening newborns for critical congenital heart disease (CCHD).1 iSpO2 Rx is a smart...